Antisense peptide nucleic acids (PNAs) are emerging as a promising tool in the fight against bacterial infections, particularly those caused by multidrug-resistant strains. These synthetic ...

The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the ...

Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

As implied in the article by Paul Smaglik, "Making Sense of Antisense" (The Scientist, 12[17]:1, Aug. 31, 1998), the clinical usefulness of antisense compounds will be determined, in large part, by ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

The partnership centres on Alloy’s AntiClastic Antisense platform ... This collaboration reflects renewed interest in nucleic acid-based therapies, particularly for CNS disorders, an area ...